✦ LIBER ✦

A human-human hybridoma secreting anti-Pseudomonas aeruginosaexotoxin-A monoclonal antibody with highly potent neutralizing activity

✍ Scribed by Masato Kuriyama; Yuzo Ichimori; Susumu Iwasa; Kyozo Tsukamoto

Publisher: Springer
Year: 1990
Tongue: English
Weight: 930 KB
Volume: 3
Category: Article
ISSN: 0920-9069
DOI: 10.1007/bf00365263

No coin nor oath required. For personal study only.

✦ Synopsis

A hybridoma secreting human monoclonal antibody (MAB) against Pseudomonas aeruginosa exotoxin A (PEA) was constructed by fusing Epstein-Barr virus-transformed peripheral blood lymphocytes with human B lymphoblastoid cell line TAW-925. The human-human hybridoma stably produced human IgG2 MAB at the rate of 0.4-0.5 microgram/ml per 10(6) cells per day for more than six months, and the MAB was capable of neutralizing the in vitro cytotoxic and in vivo lethal effects of PEA with approximately 100- and 70-fold, respectively, higher activity than serum polyclonal antibody preparations.

📜 SIMILAR VOLUMES

Generation of human B-cell hybridomas se

Generation of human B-cell hybridomas secreting monoclonal anti–myelin-associated glycoprotein antibodies from a patient with neuropathy

✍ Dr. Linda Spatz; Becky Lieberson; Judith Abraham; Orlando J. Miller; Dorothy A. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 797 KB

This heterogeneity showed that all components of the infarcted area were not equally damaged. These isointensity transverse bands were probably the spared nerve fiber bundles projecting into the cerebellar hemisphere from the contralateral pontine nuclei. In the cerebral hemispheres, the region mos

Uterine serous papillary carcinomas over

Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody

✍ Joyce Varughese; Emiliano Cocco; Stefania Bellone; Maria de Leon; Marta Bellone; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB

Immunotoxins constructed with anti-CD25

Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin a-chain have potent anti-tumour effects against human hodgkin cells in vitro and solid hodgkin tumours in mice

✍ Andreas Engert; Gary Martin; Peter Amlot; John Wijdenes; Volker Diehl; Philip Th 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 867 KB

## Abstract Twenty‐three monoclonal antibodies (MAbs) against the IL‐2 receptor α‐chain (CD25) were evaluated as ricin A‐chain immunotoxins for the treatment of Hodgkin's disease. Primary screening used an indirect assay in which the cells were treated with the test antibody followed by a Fab immun

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views